Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control
NCT02959554 · AIO-Studien-gGmbH · PHASE2 · terminated · last registry update 2021-09-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, AIO-Studien-gGmbH |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDCD1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-08-30Phase 3 first posted: Hutchmed, fruquintinib+sintilimab + axitinib / everolimus (NCT05522231)
- 2022-06-30Results posted on the registry: City of Hope Medical Center, Pembrolizumab (NCT02830594)
- 2022-06-23Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Sintilimab + Carboplatin (NCT05429463)
- 2022-01-21Phase 3 first posted: ARCAGY/ GINECO GROUP, Carboplatin-Paclitaxel + Dostarlimab (NCT05201547)
- 2021-09-17Phase 3 first posted: AstraZeneca, Trastuzumab Deruxtecan + Cisplatin (NCT05048797)
- 2021-09-14Results posted on the registry: Immunocore Ltd, IMCgp100 + Dacarbazine (NCT03070392)
- 2021-02-03Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Belzutifan (NCT04736706)
- 2020-11-03Phase 3 first posted: Mirati Therapeutics Inc., Adagrasib + Adagrasib (NCT04613596)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision